Halozyme Therapeutics Inc (HALO):企業の財務・戦略的SWOT分析

◆英語タイトル:Halozyme Therapeutics Inc (HALO) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1663
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥40,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Halozyme Therapeutics Inc (HALO) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Halozyme Therapeutics Inc (Halozyme) is a biotechnology company that develops and commercializes novel recombinant human enzymes for enhancing the delivery of biologics and drugs. The company’s marketed product, Hylenex, is a branded, recombinant formulation of rHuPH20, which enables administration of subcutaneous fluid with improved hydration, absorption and dispersion of other injected drugs and also with an enhanced resorption of radiopaque agents in subcutaneous urography. It also offers proprietary Enhanze, a drug-delivery technology built on its patented recombinant human hyaluronidase enzyme, rHuPH20. The company works in partnership with Pfizer, Roche, Baxalta, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and Argenx for advancing treatment for various cancer types. Halozyme is headquartered in San Diego, California, the US.

Halozyme Therapeutics Inc Key Recent Developments

Feb 24,2020 Halozyme announces CFO transition
Feb 24,2020 Halozyme reports fourth quarter and full year 2019 results
Jan 14,2020 Halozyme provides 2020 business update and financial guidance
Nov 12,2019 Halozyme reports third quarter 2019 results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Halozyme Therapeutics Inc – Key Facts
Halozyme Therapeutics Inc – Key Employees
Halozyme Therapeutics Inc – Key Employee Biographies
Halozyme Therapeutics Inc – Major Products and Services
Halozyme Therapeutics Inc – History
Halozyme Therapeutics Inc – Company Statement
Halozyme Therapeutics Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Halozyme Therapeutics Inc – Business Description
Product Category: Net Product Sales
Performance
Product Category: Revenue Under Collaborative Agreements
Performance
Product Category: Royalties
Performance
Geographical Segment: All Other Foreign
Performance
Geographical Segment: Switzerland
Performance
Geographical Segment: The US
Performance
R&D Overview
Halozyme Therapeutics Inc – Corporate Strategy
Halozyme Therapeutics Inc – SWOT Analysis
SWOT Analysis – Overview
Halozyme Therapeutics Inc – Strengths
Halozyme Therapeutics Inc – Weaknesses
Halozyme Therapeutics Inc – Opportunities
Halozyme Therapeutics Inc – Threats
Halozyme Therapeutics Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Halozyme Therapeutics Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 24, 2020: Halozyme announces CFO transition
Feb 24, 2020: Halozyme reports fourth quarter and full year 2019 results
Jan 14, 2020: Halozyme provides 2020 business update and financial guidance
Nov 12, 2019: Halozyme reports third quarter 2019 results
Nov 04, 2019: Halozyme announces actions to focus strategy on ENHANZE drug delivery technology
Aug 06, 2019: Halozyme reports second quarter 2019 results
May 06, 2019: Halozyme names Dr. Alison A. Armour as Senior Vice President Of Research And Development
Feb 21, 2019: Halozyme Reports Fourth Quarter And Full-Year 2018 Results
Feb 05, 2019: Argenx to leverage Halozyme’s subcutaneous drug delivery technology
Jan 09, 2019: Halozyme Provides 2019 Pipeline Update And Financial Guidance At 37th Annual JP Morgan Healthcare Conference
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Halozyme Therapeutics Inc, Key Facts
Halozyme Therapeutics Inc, Key Employees
Halozyme Therapeutics Inc, Key Employee Biographies
Halozyme Therapeutics Inc, Major Products and Services
Halozyme Therapeutics Inc, History
Halozyme Therapeutics Inc, Subsidiaries
Halozyme Therapeutics Inc, Key Competitors
Halozyme Therapeutics Inc, Ratios based on current share price
Halozyme Therapeutics Inc, Annual Ratios
Halozyme Therapeutics Inc, Annual Ratios (Cont...1)
Halozyme Therapeutics Inc, Annual Ratios (Cont...2)
Halozyme Therapeutics Inc, Interim Ratios
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Halozyme Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Halozyme Therapeutics Inc, Performance Chart (2015 - 2019)
Halozyme Therapeutics Inc, Ratio Charts
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Halozyme Therapeutics Inc (HALO):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Fortis Healthcare Ltd (FORTIS):製薬・医療:M&Aディール及び事業提携情報
    Summary Fortis Healthcare Ltd (Fortis) is an integrated healthcare provider that delivers healthcare services in the Pan Asia-Pacific region. The company’s services portfolio comprises diagnostics, primary care, day care and specialty hospitals. It owns, operates, and manages a chain of multi-specia …
  • Telenet Group Holding NV:企業の戦略・SWOT・財務分析
    Telenet Group Holding NV - Strategy, SWOT and Corporate Finance Report Summary Telenet Group Holding NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Biman Bangladesh Airlines Ltd.:企業の戦略・SWOT・財務情報
    Biman Bangladesh Airlines Ltd. - Strategy, SWOT and Corporate Finance Report Summary Biman Bangladesh Airlines Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • DLF Limited:企業の戦略・SWOT・財務情報
    DLF Limited - Strategy, SWOT and Corporate Finance Report Summary DLF Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Brodrene Hartmann AS:戦略・SWOT・企業財務分析
    Brodrene Hartmann AS - Strategy, SWOT and Corporate Finance Report Summary Brodrene Hartmann AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Inventiva (IVA)-製薬・医療分野:企業M&A・提携分析
    Summary Inventiva is a drug discovery company that endeavors to develop breakthrough therapies for cancer, fibrosis and rare diseases. The company’s product pipeline includes IVA336 for mucopolysaccharidosis type VI (MPS VI) and IVA337 for systemic sclerosis. Inventiva develops a novel internal canc …
  • Cummins Inc.:企業の戦略・SWOT・財務分析
    Cummins Inc. - Strategy, SWOT and Corporate Finance Report Summary Cummins Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Sunflower Electric Power Corporation:企業の戦略的SWOT分析
    Sunflower Electric Power Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Ontario Municipal Employees Retirement System:電力:M&Aディール及び事業提携情報
    Summary Ontario Municipal Employees Retirement System (OMERS) offers pension benefits to government employees, beneficiaries, and retirees from diverse sectors such as municipalities, libraries, police and fire departments, schools, and other agencies in Ontario. It is sponsored by OMERS Sponsors Co …
  • MDNA Life Sciences Inc-製薬・医療分野:企業M&A・提携分析
    Summary MDNA Life Sciences Inc (MDNA) is a molecular diagnostics company that develops molecular tests based on the mitochondrial genome. The company’s prostate core mitomic test (PCMT) based on the science of mitochondrial DNA (mtDNA) is a tissue-based prostate cancer diagnostics for prostate and o …
  • Oxford Biodynamics Plc:製薬・医療:M&Aディール及び事業提携情報
    Summary Oxford Biodynamics Plc (Oxford Biodynamics) is a developer of biomarker discovery platform. The company concentrates on research in detection, monitoring and prognosis of major diseases associated with aberrant gene expression such as oncology, metabolic, inflammatory, cardiovascular and neu …
  • Eurasian Natural Resources Corporation Ltd:企業のM&A・事業提携・投資動向
    Eurasian Natural Resources Corporation Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Eurasian Natural Resources Corporation Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detai …
  • Sky plc (SKY):企業の財務・戦略的SWOT分析
    Sky plc (SKY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Procurri Corporation Limited (BVQ):企業の財務・戦略的SWOT分析
    Procurri Corporation Limited (BVQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • P.T. Telekomunikasi Selular:企業の戦略・SWOT・財務情報
    P.T. Telekomunikasi Selular - Strategy, SWOT and Corporate Finance Report Summary P.T. Telekomunikasi Selular - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Bank Sepah:企業の戦略・SWOT・財務情報
    Bank Sepah - Strategy, SWOT and Corporate Finance Report Summary Bank Sepah - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • St. Augustine Gold and Copper Limited:企業の戦略・SWOT・財務情報
    St. Augustine Gold and Copper Limited - Strategy, SWOT and Corporate Finance Report Summary St. Augustine Gold and Copper Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Pharco Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Pharco Pharmaceuticals Inc (Pharco Pharmaceuticals), a subsidiary of Pharco Corp, is a manufacturer of branded and generic pharmaceutical products. The company offers products such as alambupine, alfatral, amlodipine, amrase, amrizole, bisadyl, bromhexine, carbolase, ciprofloxacin, dexametha …
  • Allan Myers Inc:企業の戦略・SWOT・財務分析
    Allan Myers Inc - Strategy, SWOT and Corporate Finance Report Summary Allan Myers Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Valero Energy Corporation:企業の戦略・SWOT・財務情報
    Valero Energy Corporation - Strategy, SWOT and Corporate Finance Report Summary Valero Energy Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆